TC
CNTA

Tejara Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Tejara Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,235
Closed -$131K – 89
2022
Q4 		$131K Buy
+42,235
New +$157K 0.08% 92

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Tejara Capital's CNTA Position: Q1 2023 in Review

Tejara Capital sold out of Centessa Pharmaceuticals (CNTA) in Q1 2023, closing a stake of 42,235 shares — an estimated $131K sold.

Tejara Capital first reported a position in CNTA in Q4 2022 and held it in 1 quarter. The position peaked at $131K in Q4 2022. 44 funds tracked by Wall St. Rank hold CNTA as of Q1 2023.

  • Tejara Capital reported no remaining Centessa Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Tejara Capital sold 42,235 Centessa Pharmaceuticals shares in Q1 2023, an estimated $131K.
  • Tejara Capital first reported a position in Centessa Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Tejara Capital's Centessa Pharmaceuticals position peaked at $131K in Q4 2022.
  • 44 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2023.

Based on Tejara Capital's 13F filing for Q1 2023, filed 12 May 2023.